Current Report Filing (8-k)
February 14 2020 - 09:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February
14, 2020
ClearPoint Neuro,
Inc.
(Exact name of registrant as specified in its charter)
|
|
|
DELAWARE |
001-34822 |
58-2394628 |
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification Number)
|
5 Musick
Irvine, CA 92618
(Address of principal executive offices, zip code)
(949) 900-6833
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each
class |
Trading Symbol(s) |
Name of each exchange on which
registered |
Common Stock, $0.01 par value per
share |
CLPT |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 7.01. |
Regulation FD Disclosure. |
On February 14, 2020, ClearPoint Neuro, Inc. (formerly MRI
Interventions, Inc.) (the “Company”) issued a press release
announcing its revenue outlook for 2020. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
On February 14, 2020, the Company also posted an updated investor
presentation to its website at
http://ir.stockpr.com/mriinterventions/investor-presentations. A
copy of the investor presentation is furnished as Exhibit 99.2 to
this Current Report on Form 8-K. The Company may use the investor
presentation from time to time in conversations with analysts,
investors and others.
The information in Item 7.01 of this Current Report on Form
8-K, as well as Exhibits 99.1 and 99.2 attached hereto, shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), nor shall
they be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a
filing.
|
Item 9.01. |
Financial Statements and
Exhibits. |
(d)
Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
Date: February 14, 2020 |
MRI INTERVENTIONS,
INC. |
|
|
|
|
By: |
/s/ Harold A. Hurwitz |
|
|
Harold A. Hurwitz |
|
|
Chief Financial Officer |
MRI Interventions (AMEX:MRIC)
Historical Stock Chart
From Dec 2020 to Jan 2021
MRI Interventions (AMEX:MRIC)
Historical Stock Chart
From Jan 2020 to Jan 2021